CLINICAL_TRIALS
trial_result
· 2013-07-31
Clinical Trial Update: Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders [Phase 3]
Summary
Update on the open-label extension of arbaclofen (STX209) for autism spectrum disorder in a Phase 3 trial, which has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Seaside Therapeutics, Inc. | Conditions: Autism Spectrum Disorders | Phase 3 | Status: TERMINATED